Vaccine value profile for herpes simplex virus
Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the H...
Saved in:
| Published in | Vaccine Vol. 42; no. 19; pp. S82 - S100 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier Ltd
25.07.2024
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2024.01.044 |
Cover
| Abstract | Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines.
This ‘Vaccine Value Profile’ (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. |
|---|---|
| AbstractList | Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines.This ‘Vaccine Value Profile’ (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines. This ‘Vaccine Value Profile’ (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. AbstractHerpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines. This ‘Vaccine Value Profile’ (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines. This 'Vaccine Value Profile' (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2 is sexually transmitted and is the leading cause of genital ulcer disease (GUD). It also increases the risk of HIV acquisition, fueling the HIV epidemic. HSV-1 is typically acquired in childhood through nonsexual contact and contributes to oral and ocular disease, but it can also be sexually transmitted to cause GUD. Both HSV-1 and HSV-2 cause neonatal herpes and neurologic disease. Given the ubiquitous nature of HSV-1 and HSV-2 infections and the limited existing prevention and control measures, vaccination would be the most efficient strategy to reduce the global burden of morbidity related to HSV infection. Vaccine strategies include prophylactic vaccination, which would prevent infection among susceptible persons and would likely be given to adolescents, and therapeutic vaccinations, which would be given to people with symptomatic genital HSV-2 infection. This document discusses the vaccine value profile of both types of vaccines. This 'Vaccine Value Profile' (VVP) for HSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by subject matter experts from academia, non-profit organizations, government agencies and multi-lateral organizations. All contributors have extensive expertise on various elements of the HSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information. |
| Author | Johnston, Christine Scheele, Suzanne Looker, Katharine Ndowa, Francis Marshall, Caroline Deal, Carolyn Boily, Marie-Claude Delany-Moretlwe, Sinead Lee, Shaun Gottlieb, Sami Bachmann, Laura Chaiyakunapruk, Nathorn Mello, Maeve B. |
| Author_xml | – sequence: 1 givenname: Christine surname: Johnston fullname: Johnston, Christine email: cjohnsto@uw.edu organization: Division of Allergy & Infectious Diseases, University of Washington, Seattle, WA, USA – sequence: 2 givenname: Suzanne surname: Scheele fullname: Scheele, Suzanne organization: Center for Vaccine Introduction and Access, PATH, Washington, DC, USA – sequence: 3 givenname: Laura surname: Bachmann fullname: Bachmann, Laura organization: Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA – sequence: 4 givenname: Marie-Claude surname: Boily fullname: Boily, Marie-Claude organization: MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, UK – sequence: 5 givenname: Nathorn surname: Chaiyakunapruk fullname: Chaiyakunapruk, Nathorn organization: Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA – sequence: 6 givenname: Carolyn surname: Deal fullname: Deal, Carolyn organization: Enteric and Sexually Transmitted Diseases Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA – sequence: 7 givenname: Sinead surname: Delany-Moretlwe fullname: Delany-Moretlwe, Sinead organization: Wits RHI, Johannesburg, South Africa – sequence: 8 givenname: Shaun surname: Lee fullname: Lee, Shaun organization: Monash University Malaysia, Subang, Malaysia – sequence: 9 givenname: Katharine surname: Looker fullname: Looker, Katharine organization: Population Health Sciences, Bristol Medical School, University of Bristol, UK – sequence: 10 givenname: Caroline surname: Marshall fullname: Marshall, Caroline organization: Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland – sequence: 11 givenname: Maeve B. surname: Mello fullname: Mello, Maeve B. organization: Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland – sequence: 12 givenname: Francis surname: Ndowa fullname: Ndowa, Francis organization: Skin and GU Medicine Clinic, Harare, Zimbabwe – sequence: 13 givenname: Sami surname: Gottlieb fullname: Gottlieb, Sami organization: Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39003018$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkktv1DAUhS1URKeFnwCKxIZNwr1-JI4QIFSVUqlSFzzEznKcO8KDJxnsZET_fRNm2sVIqF15852j63POCTvq-o4Ye4lQIGD5dlVsrXO-o4IDlwVgAVI-YQvUlci5Qn3EFsBLmUuEn8fsJKUVACiB9TN2LGoAAagXrPixc8m2NoyUbWK_9IGyZR-zXxQ3lLLk15tAf7Otj2N6zp4ubUj0Yv-esu-fz7-dfcmvri8uzz5d5U5pPuQSJG9dU8pGyrYR0rY1WtEqaipXaRJaq7J2tUJq0GruFNdca0d1U_GJBXHK3ux8p4P-jJQGs_bJUQi2o35MRqASZYlYPgKFqq5VKaSe0NcH6KofYzd95B9VaV5VM_VqT43NmlqziX5t4425C20C1A5wsU8p0vIeQTBzOWZl9uWYuRwDaKZyJt27A53zgx183w3R-vCg-uNOTVPuW0_RJOepc9T6SG4wbe8fdPhw4OCC77yz4TfdULrPAk3iBszXeT7zericl6PmqN__3-ARB9wCp1_Uiw |
| CitedBy_id | crossref_primary_10_3390_microorganisms12091846 |
| Cites_doi | 10.1056/NEJMoa0802556 10.3390/v13081637 10.1056/NEJMoa1103151 10.1016/j.vaccine.2015.12.076 10.1093/infdis/jiz225 10.1093/infdis/jix004 10.1186/s44263-024-00053-6 10.1056/NEJMoa0904849 10.1371/journal.pone.0163541 10.1186/s12916-019-1285-x 10.1172/JCI1758 10.1016/j.vaccine.2019.08.077 10.1136/bmjgh-2020-003006 10.1371/journal.pone.0017748 10.1016/j.vaccine.2018.02.067 10.1093/cid/cis226 10.1016/S1473-3099(19)30470-0 10.1016/S1473-3099(17)30405-X 10.1097/OLQ.0b013e3181d3d023 10.1016/j.idnow.2021.11.007 10.1371/journal.pmed.1003938 10.1128/JVI.79.23.14632-14639.2005 10.1128/JVI.01574-18 10.1093/infdis/jiv451 10.1002/cpz1.332 10.1016/j.virol.2013.12.014 10.1093/infdis/jit651 10.1016/j.vaccine.2008.11.074 10.15585/mmwr.rr7004a1 10.1098/rsif.2014.0160 10.1097/01.AOG.0000219749.96274.15 10.1016/j.clp.2021.03.003 10.11124/JBIES-21-00057 10.1186/s12955-022-01934-w 10.1016/S0140-6736(07)61908-4 10.1136/sextrans-2021-054972 10.1093/infdis/jiy372 10.1097/01.olq.0000237853.69443.71 10.1093/infdis/jix088 10.1258/0956462011923859 10.1016/j.vaccine.2017.03.074 10.1097/QAI.0000000000002743 10.1212/01.WNL.0000134652.51657.10 10.1056/NEJMoa035144 10.1016/j.jpeds.2007.04.065 10.1136/sti.2004.012039 10.1016/S0140-6736(00)04331-2 10.1038/s41385-019-0131-y 10.1016/j.vaccine.2019.05.009 10.1097/OLQ.0b013e3181e212e5 10.1097/QCO.0000000000000889 10.1371/journal.pone.0059037 10.1038/nature12110 10.1038/nature11522 10.1080/09286586.2021.1962919 10.1086/425271 10.1097/OLQ.0000000000000689 10.1093/infdis/jiy415 10.1128/JVI.01302-15 10.1038/s41541-020-00254-8 10.1136/bmjgh-2019-001875 10.1093/jpids/piab105 10.3389/fneur.2017.00199 10.1001/archinternmed.2009.177 10.1097/00007435-200303000-00010 10.1172/JCI142088 10.1097/OLQ.0b013e318248aa8a 10.2471/BLT.19.237149 10.1038/srep44084 10.1093/ofid/ofac494 10.1371/journal.pmed.1002475 10.1038/s41541-019-0129-1 10.1371/journal.pone.0226320 10.1086/515385 10.1016/S0140-6736(08)60920-4 10.1016/j.ebiom.2023.104530 10.1001/jama.289.2.203 10.1016/S2214-109X(16)30362-X 10.1056/NEJM199911043411904 10.7326/0003-4819-123-11-199512010-00006 10.1002/cncr.30007 10.1001/jama.280.1.61 10.1093/infdis/jir047 10.1016/j.heliyon.2020.e04368 10.1016/j.eclinm.2021.100876 10.1016/j.vaccine.2017.10.084 10.3389/fimmu.2019.00373 10.1016/j.vaccine.2014.01.053 10.1371/journal.pone.0160707 10.1093/cid/ciy943 10.1016/j.vaccine.2016.03.111 10.3855/jidc.11599 10.1056/NEJMcp1603178 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors The Authors Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. 2024. The Authors |
| Copyright_xml | – notice: 2024 The Authors – notice: The Authors – notice: Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: 2024. The Authors |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2024.01.044 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Research Library Prep AGRICOLA MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology Public Health |
| EISSN | 1873-2518 |
| EndPage | S100 |
| ExternalDocumentID | 39003018 10_1016_j_vaccine_2024_01_044 S0264410X24000550 1_s2_0_S0264410X24000550 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MR/X020258/1 – fundername: World Health Organization grantid: 001 |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFJKZ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AFCTW AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP 6I. AAFTH AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP CITATION CGR CUY CVF ECM EFLBG EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI Q9U 7X8 ACLOT ~HD 7S9 L.6 |
| ID | FETCH-LOGICAL-c582t-4042dcb64b44db34ad91a3d5eb7c78e388569c951eb1a82c528288ce9b72ad903 |
| IEDL.DBID | 7X7 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Sun Sep 28 08:00:19 EDT 2025 Sun Sep 28 01:26:25 EDT 2025 Wed Aug 13 11:27:56 EDT 2025 Sat Sep 06 11:15:17 EDT 2025 Tue Jul 01 01:07:19 EDT 2025 Thu Apr 24 22:58:41 EDT 2025 Tue Dec 03 03:45:16 EST 2024 Tue Feb 25 20:05:30 EST 2025 Tue Aug 26 16:34:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 19 |
| Keywords | Vaccine Herpes simplex virus |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c582t-4042dcb64b44db34ad91a3d5eb7c78e388569c951eb1a82c528288ce9b72ad903 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0264410X24000550 |
| PMID | 39003018 |
| PQID | 3079782778 |
| PQPubID | 105530 |
| ParticipantIDs | proquest_miscellaneous_3153661160 proquest_miscellaneous_3079956348 proquest_journals_3079782778 pubmed_primary_39003018 crossref_primary_10_1016_j_vaccine_2024_01_044 crossref_citationtrail_10_1016_j_vaccine_2024_01_044 elsevier_sciencedirect_doi_10_1016_j_vaccine_2024_01_044 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X24000550 elsevier_clinicalkey_doi_10_1016_j_vaccine_2024_01_044 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-25 |
| PublicationDateYYYYMMDD | 2024-07-25 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-25 day: 25 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands – name: Kidlington |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2024 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Corey (b0255) 2004; 350 Stanaway (b0270) 2012; 39 Burger (b0530) 2016; 122 Spicknall (b0185) 2019; 37 Ayoub, Chemaitelly, Abu-Raddad (b0485) 2020; 8 Workowski (b0235) 2021; 70 Melvin (b0065) 2022; 11 James (b0010) 2020; 98 Phipps (b0390) 2016; 213 2023 [cited 2023 05 March]; Available from World Health Organization Itzhaki (b0095) 2021; 9 Dudek (b0170) 2011; 203 Bernstein (b0470) 2019; 37 2019, World Health Organization: Geneva. Available from . Mailles (b0070) 2022; 52 Johnston, Gottlieb, Wald (b0230) 2016; 34 Looker (b0080) 2020; 5 Fife, Almekinder, Ofner (b0250) 2007; 34 Van Wagoner (b0430) 2018; 218 Johnston (b0155) 2017; 14 [cited 2023 March 16]; Available from Belshe (b0410) 2012; 366 Truong (b0355) 2019; 10 McCormick (b0090) 2022; 29 Halford (b0460) 2011; 6 Nardone (b0110) 2017; 8 Colgrove (b0175) 2014; 450–451 Chaiyakunapruk, N., et al., Estimated global and regional economic burden of genital herpes simplex virus infection among 15-49 year-olds in 2016. BMC Glob Public Health 2024; in press. Child Health and Development, et al. Belshe (b0415) 2014; 209 Gottlieb (b0515) 2019; 37 Martin (b0265) 2009; 169 Agyemang (b0225) 2017; 44 Setiawan (b0520) 2016; 11 Celum (b0285) 2008; 371 Augenbraun (b0205) 1995; 123 Koelle (b0350) 1998; 101 Schacker (b0210) 1998; 280 Burn (b0455) 2018; 217 Kawashima (b0260) 2022; 9 Geneva. Available from Agyemang (b0385) 2018; 218 Ochalek (b0525) 2020; 5 Looker, Garnett (b0145) 2005; 81 Gottlieb (b0025) 2016; 34 Bernstein (b0465) 2020; 5 Lo (b0340) 2019; 93 Xu (b0140) 2007; 151 Chandra (b0440) 2019; 14 Hook, Friedman, Awasthi (b0345) 2021; 1 Bennett (b0120) 2022; 20 Langenberg (b0150) 1999; 341 AlMukdad (b0045) 2021; 12 Silva (b0220) 2022; 19 Koelle (b0165) 2017; 7 Mailles (b0075) 2012; 54 Shin, Iwasaki (b0370) 2012; 491 Schiffer (b0400) 2014; 11 Lamers (b0160) 2015; 89 World Health Organization, Editor. 2016. Available from World Health Organization, Editor. 2018. Bernstein (b0375) 2019; 4 Ford (b0360) 2021; 131 Looker (b0190) 2017; 17 Gnann, Whitley (b0005) 2016; 375 Available from Tobian (b0275) 2009; 360 Samies, James, Kimberlin (b0085) 2021; 48 Zhu (b0365) 2013; 497 Harfouche, Maalmi, Abu-Raddad (b0055) 2021; 97 Sheffield (b0280) 2006; 108 Bernstein (b0435) 2019; 37 Bernstein (b0425) 2017; 215 Silhol (b0020) 2021; 88 Gottlieb (b0295) 2019; 37 Stone (b0490) 2023; 90 Gupta, Warren, Wald (b0040) 2007; 370 Shannon (b0380) 2017; 215 Devine (b0495) 2022; 20 Alsallaq (b0505) 2010; 37 Celum (b0290) 2010; 362 Looker (b0015) 2020; 20 Ayoub, Chemaitelly, Abu-Raddad (b0125) 2019; 17 Madebe (b0405) 2020; 14 Reitano (b0240) 1998; 178 Harfouche (b0050) 2021; 35 Venturino, Shoukat, Moghadas (b0480) 2020; 6 Broutet (b0315) 2014; 32 Todd (b0200) 2013; 8 Dropulic (b0420) 2019; 220 Freeman (b0510) 2009; 27 Stanfield (b0450) 2021; 13 Romanowski, Marina, Roberts (b0245) 2003; 30 National Institutes of Health. Strategic plan for herpes simplex virus research (2023-2028), NIH 2023. Available from Patel (b0115) 2001; 12 Kotton, Kotton (b0100) 2022; 35 Brijwal (b0130) 2019; 68 World Health Organization. Eberhardt (b0105) 2004; 63 Garnett (b0180) 2005; 191 NIAID. Royer (b0475) 2019; 12 Manguro (b0395) 2016; 11 Gray (b0195) 2001; 357 McQuillan (b0445) 2018; 304 Brown (b0135) 2003; 289 Yim (b0335) 2005; 79 Corbell (b0500) 2010; 37 Looker (b0060) 2017; 5 10.1016/j.vaccine.2024.01.044_b0215 Eberhardt (10.1016/j.vaccine.2024.01.044_b0105) 2004; 63 Garnett (10.1016/j.vaccine.2024.01.044_b0180) 2005; 191 Augenbraun (10.1016/j.vaccine.2024.01.044_b0205) 1995; 123 Koelle (10.1016/j.vaccine.2024.01.044_b0165) 2017; 7 Colgrove (10.1016/j.vaccine.2024.01.044_b0175) 2014; 450–451 Silhol (10.1016/j.vaccine.2024.01.044_b0020) 2021; 88 Agyemang (10.1016/j.vaccine.2024.01.044_b0225) 2017; 44 10.1016/j.vaccine.2024.01.044_b0325 Manguro (10.1016/j.vaccine.2024.01.044_b0395) 2016; 11 McQuillan (10.1016/j.vaccine.2024.01.044_b0445) 2018; 304 Halford (10.1016/j.vaccine.2024.01.044_b0460) 2011; 6 Madebe (10.1016/j.vaccine.2024.01.044_b0405) 2020; 14 Spicknall (10.1016/j.vaccine.2024.01.044_b0185) 2019; 37 Gray (10.1016/j.vaccine.2024.01.044_b0195) 2001; 357 Mailles (10.1016/j.vaccine.2024.01.044_b0075) 2012; 54 Hook (10.1016/j.vaccine.2024.01.044_b0345) 2021; 1 Xu (10.1016/j.vaccine.2024.01.044_b0140) 2007; 151 Tobian (10.1016/j.vaccine.2024.01.044_b0275) 2009; 360 10.1016/j.vaccine.2024.01.044_b0330 Stanfield (10.1016/j.vaccine.2024.01.044_b0450) 2021; 13 Looker (10.1016/j.vaccine.2024.01.044_b0190) 2017; 17 Fife (10.1016/j.vaccine.2024.01.044_b0250) 2007; 34 Agyemang (10.1016/j.vaccine.2024.01.044_b0385) 2018; 218 Itzhaki (10.1016/j.vaccine.2024.01.044_b0095) 2021; 9 Stanaway (10.1016/j.vaccine.2024.01.044_b0270) 2012; 39 Looker (10.1016/j.vaccine.2024.01.044_b0145) 2005; 81 Johnston (10.1016/j.vaccine.2024.01.044_b0155) 2017; 14 Burn (10.1016/j.vaccine.2024.01.044_b0455) 2018; 217 Chandra (10.1016/j.vaccine.2024.01.044_b0440) 2019; 14 Harfouche (10.1016/j.vaccine.2024.01.044_b0050) 2021; 35 Stone (10.1016/j.vaccine.2024.01.044_b0490) 2023; 90 Melvin (10.1016/j.vaccine.2024.01.044_b0065) 2022; 11 Samies (10.1016/j.vaccine.2024.01.044_b0085) 2021; 48 Ayoub (10.1016/j.vaccine.2024.01.044_b0125) 2019; 17 Harfouche (10.1016/j.vaccine.2024.01.044_b0055) 2021; 97 Looker (10.1016/j.vaccine.2024.01.044_b0060) 2017; 5 Bernstein (10.1016/j.vaccine.2024.01.044_b0375) 2019; 4 Ochalek (10.1016/j.vaccine.2024.01.044_b0525) 2020; 5 James (10.1016/j.vaccine.2024.01.044_b0010) 2020; 98 AlMukdad (10.1016/j.vaccine.2024.01.044_b0045) 2021; 12 Alsallaq (10.1016/j.vaccine.2024.01.044_b0505) 2010; 37 Looker (10.1016/j.vaccine.2024.01.044_b0080) 2020; 5 Gupta (10.1016/j.vaccine.2024.01.044_b0040) 2007; 370 Royer (10.1016/j.vaccine.2024.01.044_b0475) 2019; 12 Dudek (10.1016/j.vaccine.2024.01.044_b0170) 2011; 203 Corbell (10.1016/j.vaccine.2024.01.044_b0500) 2010; 37 Schacker (10.1016/j.vaccine.2024.01.044_b0210) 1998; 280 Looker (10.1016/j.vaccine.2024.01.044_b0015) 2020; 20 Belshe (10.1016/j.vaccine.2024.01.044_b0410) 2012; 366 Zhu (10.1016/j.vaccine.2024.01.044_b0365) 2013; 497 Workowski (10.1016/j.vaccine.2024.01.044_b0235) 2021; 70 Gottlieb (10.1016/j.vaccine.2024.01.044_b0295) 2019; 37 Silva (10.1016/j.vaccine.2024.01.044_b0220) 2022; 19 Burger (10.1016/j.vaccine.2024.01.044_b0530) 2016; 122 Ayoub (10.1016/j.vaccine.2024.01.044_b0485) 2020; 8 Corey (10.1016/j.vaccine.2024.01.044_b0255) 2004; 350 Broutet (10.1016/j.vaccine.2024.01.044_b0315) 2014; 32 Dropulic (10.1016/j.vaccine.2024.01.044_b0420) 2019; 220 Johnston (10.1016/j.vaccine.2024.01.044_b0230) 2016; 34 Gnann (10.1016/j.vaccine.2024.01.044_b0005) 2016; 375 Truong (10.1016/j.vaccine.2024.01.044_b0355) 2019; 10 10.1016/j.vaccine.2024.01.044_b0300 McCormick (10.1016/j.vaccine.2024.01.044_b0090) 2022; 29 Yim (10.1016/j.vaccine.2024.01.044_b0335) 2005; 79 Setiawan (10.1016/j.vaccine.2024.01.044_b0520) 2016; 11 Reitano (10.1016/j.vaccine.2024.01.044_b0240) 1998; 178 Gottlieb (10.1016/j.vaccine.2024.01.044_b0025) 2016; 34 Celum (10.1016/j.vaccine.2024.01.044_b0285) 2008; 371 Venturino (10.1016/j.vaccine.2024.01.044_b0480) 2020; 6 Sheffield (10.1016/j.vaccine.2024.01.044_b0280) 2006; 108 Patel (10.1016/j.vaccine.2024.01.044_b0115) 2001; 12 Todd (10.1016/j.vaccine.2024.01.044_b0200) 2013; 8 Bernstein (10.1016/j.vaccine.2024.01.044_b0465) 2020; 5 Langenberg (10.1016/j.vaccine.2024.01.044_b0150) 1999; 341 Ford (10.1016/j.vaccine.2024.01.044_b0360) 2021; 131 Shannon (10.1016/j.vaccine.2024.01.044_b0380) 2017; 215 Gottlieb (10.1016/j.vaccine.2024.01.044_b0515) 2019; 37 Bernstein (10.1016/j.vaccine.2024.01.044_b0470) 2019; 37 Lo (10.1016/j.vaccine.2024.01.044_b0340) 2019; 93 Freeman (10.1016/j.vaccine.2024.01.044_b0510) 2009; 27 Phipps (10.1016/j.vaccine.2024.01.044_b0390) 2016; 213 Kawashima (10.1016/j.vaccine.2024.01.044_b0260) 2022; 9 Martin (10.1016/j.vaccine.2024.01.044_b0265) 2009; 169 Schiffer (10.1016/j.vaccine.2024.01.044_b0400) 2014; 11 Bennett (10.1016/j.vaccine.2024.01.044_b0120) 2022; 20 Celum (10.1016/j.vaccine.2024.01.044_b0290) 2010; 362 Nardone (10.1016/j.vaccine.2024.01.044_b0110) 2017; 8 Lamers (10.1016/j.vaccine.2024.01.044_b0160) 2015; 89 Brown (10.1016/j.vaccine.2024.01.044_b0135) 2003; 289 Mailles (10.1016/j.vaccine.2024.01.044_b0070) 2022; 52 10.1016/j.vaccine.2024.01.044_b0320 10.1016/j.vaccine.2024.01.044_b0305 Van Wagoner (10.1016/j.vaccine.2024.01.044_b0430) 2018; 218 Devine (10.1016/j.vaccine.2024.01.044_b0495) 2022; 20 Romanowski (10.1016/j.vaccine.2024.01.044_b0245) 2003; 30 Koelle (10.1016/j.vaccine.2024.01.044_b0350) 1998; 101 Shin (10.1016/j.vaccine.2024.01.044_b0370) 2012; 491 Bernstein (10.1016/j.vaccine.2024.01.044_b0435) 2019; 37 Belshe (10.1016/j.vaccine.2024.01.044_b0415) 2014; 209 10.1016/j.vaccine.2024.01.044_b0030 Kotton (10.1016/j.vaccine.2024.01.044_b0100) 2022; 35 Brijwal (10.1016/j.vaccine.2024.01.044_b0130) 2019; 68 Bernstein (10.1016/j.vaccine.2024.01.044_b0425) 2017; 215 10.1016/j.vaccine.2024.01.044_b0035 10.1016/j.vaccine.2024.01.044_b0310 |
| References_xml | – volume: 8 start-page: 199 year: 2017 ident: b0110 article-title: Herpes simplex virus type 2 Myelitis: Case report and review of the literature publication-title: Front Neurol – volume: 20 start-page: 25 year: 2022 ident: b0495 article-title: Health-related quality of life in individuals with genital herpes: a systematic review publication-title: Health Qual Life Outcomes – volume: 12 start-page: 640 year: 2001 end-page: 645 ident: b0115 article-title: Patients' perspectives on the burden of recurrent genital herpes publication-title: Int J STD AIDS – volume: 20 start-page: 240 year: 2020 end-page: 249 ident: b0015 article-title: Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data publication-title: Lancet Infect Dis – volume: 20 start-page: 1406 year: 2022 end-page: 1473 ident: b0120 article-title: Impact of primary and recurrent genital herpes on the quality of life of young people and adults: a mixed methods systematic review publication-title: JBI Evid Synth – volume: 178 start-page: 603 year: 1998 end-page: 610 ident: b0240 article-title: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group publication-title: J Infect Dis – reference: National Institutes of Health. Strategic plan for herpes simplex virus research (2023-2028), NIH 2023. Available from: – volume: 5 year: 2020 ident: b0525 article-title: Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries publication-title: BMJ Glob Health – volume: 35 start-page: 530 year: 2022 end-page: 535 ident: b0100 article-title: Resistant herpes simplex virus infections - who, when, and what's new? publication-title: Curr Opin Infect Dis – reference: , World Health Organization, Editor. 2016. Available from: – volume: 12 year: 2021 ident: b0045 article-title: Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression publication-title: Lancet Reg Health West Pac – reference: . 2023 [cited 2023 05 March]; Available from: – volume: 98 start-page: 315 year: 2020 end-page: 329 ident: b0010 article-title: Herpes simplex virus: global infection prevalence and incidence estimates, 2016 publication-title: Bull World Health Organ – volume: 30 start-page: 226 year: 2003 end-page: 231 ident: b0245 article-title: Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study publication-title: Sex Transm Dis – volume: 491 start-page: 463 year: 2012 end-page: 467 ident: b0370 article-title: A vaccine strategy that protects against genital herpes by establishing local memory T cells publication-title: Nature – volume: 34 start-page: 297 year: 2007 end-page: 301 ident: b0250 article-title: A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir publication-title: Sex Transm Dis – volume: 29 start-page: 353 year: 2022 end-page: 362 ident: b0090 article-title: Incidence of herpes simplex virus keratitis and other ocular disease: Global review and estimates publication-title: Ophthalmic Epidemiol – volume: 341 start-page: 1432 year: 1999 end-page: 1438 ident: b0150 article-title: A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group publication-title: N Engl J Med – volume: 37 start-page: 7336 year: 2019 end-page: 7345 ident: b0295 article-title: Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling publication-title: Vaccine – reference: 2019, World Health Organization: Geneva. Available from: – volume: 27 start-page: 940 year: 2009 end-page: 946 ident: b0510 article-title: Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa publication-title: Vaccine – volume: 209 start-page: 828 year: 2014 end-page: 836 ident: b0415 article-title: Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women publication-title: J Infect Dis – volume: 218 start-page: 1691 year: 2018 end-page: 1699 ident: b0385 article-title: Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals publication-title: J Infect Dis – volume: 90 year: 2023 ident: b0490 article-title: The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study publication-title: EBioMedicine – volume: 497 start-page: 494 year: 2013 end-page: 497 ident: b0365 article-title: Immune surveillance by CD8 αα + skin-resident T cells in human herpes virus infection publication-title: Nature – volume: 93 year: 2019 ident: b0340 article-title: Acute infection and subsequent subclinical reactivation of herpes simplex virus 2 after vaginal inoculation of rhesus macaques publication-title: J Virol – volume: 11 start-page: e0160707 year: 2016 ident: b0520 article-title: Assessment of the broader economic consequences of HPV prevention from a government-perspective: A fiscal analytic approach publication-title: PLoS One – volume: 52 start-page: 1 year: 2022 end-page: 6 ident: b0070 article-title: Changing profile of encephalitis: Results of a 4-year study in France publication-title: Infect Dis Now – volume: 4 start-page: 33 year: 2019 ident: b0375 article-title: Successful application of prime and pull strategy for a therapeutic HSV vaccine publication-title: NPJ Vaccines – volume: 37 start-page: 7408 year: 2019 end-page: 7418 ident: b0515 article-title: Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017 publication-title: Vaccine – volume: 5 start-page: e300 year: 2017 end-page: e309 ident: b0060 article-title: First estimates of the global and regional incidence of neonatal herpes infection publication-title: Lancet Glob Health – reference: , World Health Organization, Editor. 2018. – volume: 11 start-page: 94 year: 2022 end-page: 101 ident: b0065 article-title: Neonatal herpes simplex virus infection: Epidemiology and outcomes in the modern era publication-title: J Pediatric Infect Dis Soc – volume: 360 start-page: 1298 year: 2009 end-page: 1309 ident: b0275 article-title: Male circumcision for the prevention of HSV-2 and HPV infections and syphilis publication-title: N Engl J Med – volume: 10 start-page: 373 year: 2019 ident: b0355 article-title: Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design publication-title: Front Immunol – volume: 215 start-page: 856 year: 2017 end-page: 864 ident: b0425 article-title: therapeutic vaccine for genital herpes simplex Virus-2 Infection: Findings from a randomized trial publication-title: J Infect Dis – volume: 375 start-page: 666 year: 2016 end-page: 674 ident: b0005 article-title: Genital herpes publication-title: N Engl J Med – volume: 203 start-page: 1434 year: 2011 end-page: 1441 ident: b0170 article-title: Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa publication-title: J Infect Dis – volume: 350 start-page: 11 year: 2004 end-page: 20 ident: b0255 article-title: Once-daily valacyclovir to reduce the risk of transmission of genital herpes publication-title: N Engl J Med – volume: 370 start-page: 2127 year: 2007 end-page: 2137 ident: b0040 article-title: Genital herpes publication-title: Lancet – volume: 68 start-page: 1783 year: 2019 end-page: 1784 ident: b0130 article-title: Herpes simplex virus type 1 genital ulcer disease at a tertiary care hospital in north india publication-title: Clin Infect Dis – volume: 37 start-page: 3443 year: 2019 end-page: 3450 ident: b0435 article-title: Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease publication-title: Vaccine – volume: 6 start-page: e04368 year: 2020 ident: b0480 article-title: Dynamics of HSV-2 infection with a therapeutic vaccine publication-title: Heliyon – volume: 97 start-page: 490 year: 2021 end-page: 500 ident: b0055 article-title: Epidemiology of herpes simplex virus type 2 in Latin America and the Caribbean: systematic review, meta-analyses and metaregressions publication-title: Sex Transm Infect – volume: 1 start-page: e332 year: 2021 ident: b0345 article-title: Guinea pig and mouse models for genital herpes infection publication-title: Curr Protoc – volume: 14 start-page: e0226320 year: 2019 ident: b0440 article-title: Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial publication-title: PLoS One – volume: 5 start-page: e001875 year: 2020 ident: b0080 article-title: The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study publication-title: BMJ Glob Health – reference: NIAID. – volume: 37 start-page: 488 year: 2010 end-page: 493 ident: b0500 article-title: Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries publication-title: Sex Transm Dis – reference: World Health Organization. – volume: 13 year: 2021 ident: b0450 article-title: Rational design of live-attenuated vaccines against herpes simplex viruses publication-title: Viruses – volume: 19 start-page: e1003938 year: 2022 ident: b0220 article-title: Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: A modeling study publication-title: PLoS Med – volume: 34 start-page: 2939 year: 2016 end-page: 2947 ident: b0025 article-title: The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps publication-title: Vaccine – reference: World Health Organization, – volume: 357 start-page: 1149 year: 2001 end-page: 1153 ident: b0195 article-title: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai publication-title: Lancet – volume: 11 year: 2014 ident: b0400 article-title: Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding publication-title: J R Soc Interface – volume: 37 start-page: 6470 year: 2019 end-page: 6477 ident: b0470 article-title: Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes publication-title: Vaccine – volume: 289 start-page: 203 year: 2003 end-page: 209 ident: b0135 article-title: Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant publication-title: JAMA – volume: 131 year: 2021 ident: b0360 article-title: B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin publication-title: J Clin Invest – volume: 14 start-page: 398 year: 2020 end-page: 403 ident: b0405 article-title: Herpes Simplex virus type 2 seroprevalence and risk factors among adolescents and youth with HIV-1 in Northern publication-title: J Infect Dev Ctries – volume: 5 start-page: 104 year: 2020 ident: b0465 article-title: The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model publication-title: npj Vaccines – reference: . Available from: – volume: 9 year: 2021 ident: b0095 article-title: Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in alzheimer's disease (AD); Underwhelming evidence against publication-title: Vaccines (Basel) – volume: 35 year: 2021 ident: b0050 article-title: Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions publication-title: EClinicalMedicine – volume: 450–451 start-page: 140 year: 2014 end-page: 145 ident: b0175 article-title: Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain publication-title: Virology – reference: Geneva. Available from: – volume: 32 start-page: 1630 year: 2014 end-page: 1637 ident: b0315 article-title: Vaccines against sexually transmitted infections: the way forward publication-title: Vaccine – volume: 304 start-page: 1 year: 2018 end-page: 8 ident: b0445 article-title: Prevalence of herpes simplex virus Type 1 and Type 2 in Persons Aged 14–49: United States, 2015–2016 publication-title: NCHS Data Brief – volume: 220 start-page: 990 year: 2019 end-page: 1000 ident: b0420 article-title: A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection publication-title: J Infect Dis – volume: 6 start-page: e17748 year: 2011 ident: b0460 article-title: A Live-Attenuated HSV-2 ICP0- Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine publication-title: PLoS One – volume: 215 start-page: 1366 year: 2017 end-page: 1375 ident: b0380 article-title: Distinct Effects of the Cervicovaginal Microbiota and Herpes Simplex Type 2 Infection on Female Genital Tract Immunology publication-title: J Infect Dis – volume: 213 start-page: 439 year: 2016 end-page: 447 ident: b0390 article-title: Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda publication-title: J Infect Dis – volume: 280 start-page: 61 year: 1998 end-page: 66 ident: b0210 article-title: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men publication-title: JAMA – volume: 8 year: 2020 ident: b0485 article-title: Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses publication-title: Vaccines (Basel) – volume: 34 start-page: 2948 year: 2016 end-page: 2952 ident: b0230 article-title: Status of vaccine research and development of vaccines for herpes simplex virus publication-title: Vaccine – volume: 362 start-page: 427 year: 2010 end-page: 439 ident: b0290 article-title: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2 publication-title: N Engl J Med – volume: 81 start-page: 103 year: 2005 end-page: 107 ident: b0145 article-title: A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2 publication-title: Sex Transm Infect – volume: 169 start-page: 1233 year: 2009 end-page: 1240 ident: b0265 article-title: A pooled analysis of the effect of condoms in preventing HSV-2 acquisition publication-title: Arch Intern Med – volume: 39 start-page: 388 year: 2012 end-page: 393 ident: b0270 article-title: Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition publication-title: Sex Transm Dis – volume: 218 start-page: 1890 year: 2018 end-page: 1899 ident: b0430 article-title: Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex Virus-2, on Viral shedding and lesions: results of a randomized placebo-controlled trial publication-title: J Infect Dis – reference: . [cited 2023 March 16]; Available from: – volume: 12 start-page: 827 year: 2019 end-page: 839 ident: b0475 article-title: Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection publication-title: Mucosal Immunol – volume: 9 start-page: p. ofac494 year: 2022 ident: b0260 publication-title: Open Forum Infect Dis – volume: 37 start-page: 290 year: 2010 end-page: 297 ident: b0505 article-title: Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2 publication-title: Sex Transm Dis – volume: 79 start-page: 14632 year: 2005 end-page: 14639 ident: b0335 article-title: The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies publication-title: J Virol – volume: 151 start-page: 374 year: 2007 end-page: 377 ident: b0140 article-title: Seroprevalence of herpes simplex virus type 1 in children in the United States publication-title: J Pediatr – volume: 371 start-page: 2109 year: 2008 end-page: 2119 ident: b0285 article-title: Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial publication-title: Lancet – reference: Child Health and Development, et al., – volume: 48 start-page: 263 year: 2021 end-page: 274 ident: b0085 article-title: Neonatal Herpes Simplex Virus Disease: Updates and Continued Challenges publication-title: Clin Perinatol – volume: 54 start-page: 1455 year: 2012 end-page: 1464 ident: b0075 article-title: Long-term outcome of patients presenting with acute infectious encephalitis of various causes in France publication-title: Clin Infect Dis – volume: 17 start-page: 57 year: 2019 ident: b0125 article-title: Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions publication-title: BMC Med – reference: Chaiyakunapruk, N., et al., Estimated global and regional economic burden of genital herpes simplex virus infection among 15-49 year-olds in 2016. BMC Glob Public Health 2024; in press. – volume: 37 start-page: 7396 year: 2019 end-page: 7407 ident: b0185 article-title: Review of mathematical models of HSV-2 vaccination: Implications for vaccine development publication-title: Vaccine – volume: 14 start-page: e1002475 year: 2017 ident: b0155 article-title: Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study publication-title: PLoS Med – volume: 89 start-page: 8206 year: 2015 end-page: 8218 ident: b0160 article-title: Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins publication-title: J Virol – volume: 70 start-page: 1 year: 2021 end-page: 187 ident: b0235 article-title: Sexually Transmitted Infections Treatment Guidelines, 2021 publication-title: MMWR Recomm Rep – volume: 44 start-page: 763 year: 2017 end-page: 767 ident: b0225 article-title: Performance of commercial enzyme-linked immunoassays for diagnosis of herpes simplex virus-1 and herpes simplex virus-2 infection in a clinical setting publication-title: Sex Transm Dis – volume: 108 start-page: 141 year: 2006 end-page: 147 ident: b0280 article-title: Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial publication-title: Obstet Gynecol – reference: . – volume: 123 start-page: 845 year: 1995 end-page: 847 ident: b0205 article-title: Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women publication-title: Ann Intern Med – volume: 8 start-page: e59037 year: 2013 ident: b0200 article-title: Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania publication-title: PLoS One – volume: 101 start-page: 1500 year: 1998 end-page: 1508 ident: b0350 article-title: Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes publication-title: J Clin Invest – volume: 217 start-page: 754 year: 2018 end-page: 758 ident: b0455 article-title: A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2 publication-title: J Infect Dis – volume: 63 start-page: 758 year: 2004 end-page: 759 ident: b0105 article-title: HSV-2 sacral radiculitis (Elsberg syndrome) publication-title: Neurology – volume: 11 start-page: e0163541 year: 2016 ident: b0395 article-title: Genital HSV Shedding among Kenyan Women Initiating Antiretroviral Therapy publication-title: PLoS One – volume: 88 start-page: 19 year: 2021 end-page: 30 ident: b0020 article-title: What is the burden of heterosexually acquired HIV due to HSV-2? global and regional model-based estimates of the proportion and number of HIV infections attributable to HSV-2 infection publication-title: J Acquir Immune Defic Syndr – volume: 122 start-page: 2057 year: 2016 end-page: 2066 ident: b0530 article-title: Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines publication-title: Cancer – volume: 7 start-page: 44084 year: 2017 ident: b0165 article-title: Worldwide circulation of HSV-2 × HSV-1 recombinant strains publication-title: Sci Rep – volume: 366 start-page: 34 year: 2012 end-page: 43 ident: b0410 article-title: Efficacy results of a trial of a herpes simplex vaccine publication-title: N Engl J Med – volume: 191 start-page: S97 year: 2005 end-page: S ident: b0180 article-title: Role of herd immunity in determining the effect of vaccines against sexually transmitted disease publication-title: J Infect Dis – volume: 17 start-page: 1303 year: 2017 end-page: 1316 ident: b0190 article-title: Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis publication-title: Lancet Infect Dis – volume: 360 start-page: 1298 issue: 13 year: 2009 ident: 10.1016/j.vaccine.2024.01.044_b0275 article-title: Male circumcision for the prevention of HSV-2 and HPV infections and syphilis publication-title: N Engl J Med doi: 10.1056/NEJMoa0802556 – volume: 13 issue: 8 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0450 article-title: Rational design of live-attenuated vaccines against herpes simplex viruses publication-title: Viruses doi: 10.3390/v13081637 – volume: 366 start-page: 34 issue: 1 year: 2012 ident: 10.1016/j.vaccine.2024.01.044_b0410 article-title: Efficacy results of a trial of a herpes simplex vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa1103151 – volume: 34 start-page: 2948 issue: 26 year: 2016 ident: 10.1016/j.vaccine.2024.01.044_b0230 article-title: Status of vaccine research and development of vaccines for herpes simplex virus publication-title: Vaccine doi: 10.1016/j.vaccine.2015.12.076 – volume: 220 start-page: 990 issue: 6 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0420 article-title: A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection publication-title: J Infect Dis doi: 10.1093/infdis/jiz225 – volume: 215 start-page: 856 issue: 6 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0425 article-title: therapeutic vaccine for genital herpes simplex Virus-2 Infection: Findings from a randomized trial publication-title: J Infect Dis doi: 10.1093/infdis/jix004 – ident: 10.1016/j.vaccine.2024.01.044_b0215 doi: 10.1186/s44263-024-00053-6 – volume: 362 start-page: 427 issue: 5 year: 2010 ident: 10.1016/j.vaccine.2024.01.044_b0290 article-title: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2 publication-title: N Engl J Med doi: 10.1056/NEJMoa0904849 – volume: 11 start-page: e0163541 issue: 9 year: 2016 ident: 10.1016/j.vaccine.2024.01.044_b0395 article-title: Genital HSV Shedding among Kenyan Women Initiating Antiretroviral Therapy publication-title: PLoS One doi: 10.1371/journal.pone.0163541 – volume: 17 start-page: 57 issue: 1 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0125 article-title: Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: model-based predictions publication-title: BMC Med doi: 10.1186/s12916-019-1285-x – volume: 101 start-page: 1500 issue: 7 year: 1998 ident: 10.1016/j.vaccine.2024.01.044_b0350 article-title: Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes publication-title: J Clin Invest doi: 10.1172/JCI1758 – ident: 10.1016/j.vaccine.2024.01.044_b0325 – volume: 37 start-page: 6470 issue: 43 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0470 article-title: Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes publication-title: Vaccine doi: 10.1016/j.vaccine.2019.08.077 – volume: 5 issue: 10 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0525 article-title: Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries publication-title: BMJ Glob Health doi: 10.1136/bmjgh-2020-003006 – volume: 304 start-page: 1 year: 2018 ident: 10.1016/j.vaccine.2024.01.044_b0445 article-title: Prevalence of herpes simplex virus Type 1 and Type 2 in Persons Aged 14–49: United States, 2015–2016 publication-title: NCHS Data Brief – volume: 6 start-page: e17748 issue: 3 year: 2011 ident: 10.1016/j.vaccine.2024.01.044_b0460 article-title: A Live-Attenuated HSV-2 ICP0- Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine publication-title: PLoS One doi: 10.1371/journal.pone.0017748 – volume: 37 start-page: 7396 issue: 50 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0185 article-title: Review of mathematical models of HSV-2 vaccination: Implications for vaccine development publication-title: Vaccine doi: 10.1016/j.vaccine.2018.02.067 – volume: 54 start-page: 1455 issue: 10 year: 2012 ident: 10.1016/j.vaccine.2024.01.044_b0075 article-title: Long-term outcome of patients presenting with acute infectious encephalitis of various causes in France publication-title: Clin Infect Dis doi: 10.1093/cid/cis226 – volume: 20 start-page: 240 issue: 2 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0015 article-title: Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(19)30470-0 – volume: 17 start-page: 1303 issue: 12 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0190 article-title: Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(17)30405-X – volume: 8 issue: 3 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0485 article-title: Epidemiological Impact of Novel Preventive and Therapeutic HSV-2 Vaccination in the United States: Mathematical Modeling Analyses publication-title: Vaccines (Basel) – volume: 37 start-page: 290 issue: 5 year: 2010 ident: 10.1016/j.vaccine.2024.01.044_b0505 article-title: Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2 publication-title: Sex Transm Dis doi: 10.1097/OLQ.0b013e3181d3d023 – volume: 52 start-page: 1 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0070 article-title: Changing profile of encephalitis: Results of a 4-year study in France publication-title: Infect Dis Now doi: 10.1016/j.idnow.2021.11.007 – volume: 19 start-page: e1003938 issue: 12 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0220 article-title: Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: A modeling study publication-title: PLoS Med doi: 10.1371/journal.pmed.1003938 – volume: 79 start-page: 14632 issue: 23 year: 2005 ident: 10.1016/j.vaccine.2024.01.044_b0335 article-title: The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies publication-title: J Virol doi: 10.1128/JVI.79.23.14632-14639.2005 – volume: 93 issue: 2 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0340 article-title: Acute infection and subsequent subclinical reactivation of herpes simplex virus 2 after vaginal inoculation of rhesus macaques publication-title: J Virol doi: 10.1128/JVI.01574-18 – ident: 10.1016/j.vaccine.2024.01.044_b0030 – volume: 213 start-page: 439 issue: 3 year: 2016 ident: 10.1016/j.vaccine.2024.01.044_b0390 article-title: Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda publication-title: J Infect Dis doi: 10.1093/infdis/jiv451 – volume: 1 start-page: e332 issue: 12 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0345 article-title: Guinea pig and mouse models for genital herpes infection publication-title: Curr Protoc doi: 10.1002/cpz1.332 – volume: 450–451 start-page: 140 year: 2014 ident: 10.1016/j.vaccine.2024.01.044_b0175 article-title: Genomic sequences of a low passage herpes simplex virus 2 clinical isolate and its plaque-purified derivative strain publication-title: Virology doi: 10.1016/j.virol.2013.12.014 – volume: 209 start-page: 828 issue: 6 year: 2014 ident: 10.1016/j.vaccine.2024.01.044_b0415 article-title: Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women publication-title: J Infect Dis doi: 10.1093/infdis/jit651 – volume: 27 start-page: 940 issue: 6 year: 2009 ident: 10.1016/j.vaccine.2024.01.044_b0510 article-title: Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa publication-title: Vaccine doi: 10.1016/j.vaccine.2008.11.074 – volume: 70 start-page: 1 issue: 4 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0235 article-title: Sexually Transmitted Infections Treatment Guidelines, 2021 publication-title: MMWR Recomm Rep doi: 10.15585/mmwr.rr7004a1 – ident: 10.1016/j.vaccine.2024.01.044_b0320 – volume: 11 issue: 95 year: 2014 ident: 10.1016/j.vaccine.2024.01.044_b0400 article-title: Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding publication-title: J R Soc Interface doi: 10.1098/rsif.2014.0160 – volume: 9 issue: 6 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0095 article-title: Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in alzheimer's disease (AD); Underwhelming evidence against publication-title: Vaccines (Basel) – volume: 108 start-page: 141 issue: 1 year: 2006 ident: 10.1016/j.vaccine.2024.01.044_b0280 article-title: Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial publication-title: Obstet Gynecol doi: 10.1097/01.AOG.0000219749.96274.15 – volume: 48 start-page: 263 issue: 2 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0085 article-title: Neonatal Herpes Simplex Virus Disease: Updates and Continued Challenges publication-title: Clin Perinatol doi: 10.1016/j.clp.2021.03.003 – volume: 20 start-page: 1406 issue: 6 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0120 article-title: Impact of primary and recurrent genital herpes on the quality of life of young people and adults: a mixed methods systematic review publication-title: JBI Evid Synth doi: 10.11124/JBIES-21-00057 – ident: 10.1016/j.vaccine.2024.01.044_b0300 – volume: 20 start-page: 25 issue: 1 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0495 article-title: Health-related quality of life in individuals with genital herpes: a systematic review publication-title: Health Qual Life Outcomes doi: 10.1186/s12955-022-01934-w – volume: 370 start-page: 2127 issue: 9605 year: 2007 ident: 10.1016/j.vaccine.2024.01.044_b0040 article-title: Genital herpes publication-title: Lancet doi: 10.1016/S0140-6736(07)61908-4 – volume: 97 start-page: 490 issue: 7 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0055 article-title: Epidemiology of herpes simplex virus type 2 in Latin America and the Caribbean: systematic review, meta-analyses and metaregressions publication-title: Sex Transm Infect doi: 10.1136/sextrans-2021-054972 – volume: 218 start-page: 1691 issue: 11 year: 2018 ident: 10.1016/j.vaccine.2024.01.044_b0385 article-title: Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals publication-title: J Infect Dis doi: 10.1093/infdis/jiy372 – volume: 34 start-page: 297 issue: 5 year: 2007 ident: 10.1016/j.vaccine.2024.01.044_b0250 article-title: A comparison of one year of episodic or suppressive treatment of recurrent genital herpes with valacyclovir publication-title: Sex Transm Dis doi: 10.1097/01.olq.0000237853.69443.71 – volume: 215 start-page: 1366 issue: 9 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0380 article-title: Distinct Effects of the Cervicovaginal Microbiota and Herpes Simplex Type 2 Infection on Female Genital Tract Immunology publication-title: J Infect Dis doi: 10.1093/infdis/jix088 – volume: 12 start-page: 640 issue: 10 year: 2001 ident: 10.1016/j.vaccine.2024.01.044_b0115 article-title: Patients' perspectives on the burden of recurrent genital herpes publication-title: Int J STD AIDS doi: 10.1258/0956462011923859 – volume: 37 start-page: 7336 issue: 50 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0295 article-title: Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling publication-title: Vaccine doi: 10.1016/j.vaccine.2017.03.074 – volume: 88 start-page: 19 issue: 1 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0020 article-title: What is the burden of heterosexually acquired HIV due to HSV-2? global and regional model-based estimates of the proportion and number of HIV infections attributable to HSV-2 infection publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000002743 – volume: 63 start-page: 758 issue: 4 year: 2004 ident: 10.1016/j.vaccine.2024.01.044_b0105 article-title: HSV-2 sacral radiculitis (Elsberg syndrome) publication-title: Neurology doi: 10.1212/01.WNL.0000134652.51657.10 – volume: 350 start-page: 11 issue: 1 year: 2004 ident: 10.1016/j.vaccine.2024.01.044_b0255 article-title: Once-daily valacyclovir to reduce the risk of transmission of genital herpes publication-title: N Engl J Med doi: 10.1056/NEJMoa035144 – volume: 217 start-page: 754 issue: 5 year: 2018 ident: 10.1016/j.vaccine.2024.01.044_b0455 article-title: A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2 publication-title: J Infect Dis – volume: 151 start-page: 374 issue: 4 year: 2007 ident: 10.1016/j.vaccine.2024.01.044_b0140 article-title: Seroprevalence of herpes simplex virus type 1 in children in the United States publication-title: J Pediatr doi: 10.1016/j.jpeds.2007.04.065 – volume: 81 start-page: 103 issue: 2 year: 2005 ident: 10.1016/j.vaccine.2024.01.044_b0145 article-title: A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2 publication-title: Sex Transm Infect doi: 10.1136/sti.2004.012039 – volume: 357 start-page: 1149 issue: 9263 year: 2001 ident: 10.1016/j.vaccine.2024.01.044_b0195 article-title: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai publication-title: Uganda Lancet doi: 10.1016/S0140-6736(00)04331-2 – volume: 12 start-page: 827 issue: 3 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0475 article-title: Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection publication-title: Mucosal Immunol doi: 10.1038/s41385-019-0131-y – volume: 37 start-page: 3443 issue: 26 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0435 article-title: Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease publication-title: Vaccine doi: 10.1016/j.vaccine.2019.05.009 – volume: 37 start-page: 488 issue: 8 year: 2010 ident: 10.1016/j.vaccine.2024.01.044_b0500 article-title: Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries publication-title: Sex Transm Dis doi: 10.1097/OLQ.0b013e3181e212e5 – ident: 10.1016/j.vaccine.2024.01.044_b0305 – volume: 35 start-page: 530 issue: 6 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0100 article-title: Resistant herpes simplex virus infections - who, when, and what's new? publication-title: Curr Opin Infect Dis doi: 10.1097/QCO.0000000000000889 – volume: 8 start-page: e59037 issue: 3 year: 2013 ident: 10.1016/j.vaccine.2024.01.044_b0200 article-title: Effect of genital herpes on cervicovaginal HIV shedding in women co-infected with HIV AND HSV-2 in Tanzania publication-title: PLoS One doi: 10.1371/journal.pone.0059037 – volume: 497 start-page: 494 issue: 7450 year: 2013 ident: 10.1016/j.vaccine.2024.01.044_b0365 article-title: Immune surveillance by CD8 αα + skin-resident T cells in human herpes virus infection publication-title: Nature doi: 10.1038/nature12110 – volume: 491 start-page: 463 issue: 7424 year: 2012 ident: 10.1016/j.vaccine.2024.01.044_b0370 article-title: A vaccine strategy that protects against genital herpes by establishing local memory T cells publication-title: Nature doi: 10.1038/nature11522 – volume: 29 start-page: 353 issue: 4 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0090 article-title: Incidence of herpes simplex virus keratitis and other ocular disease: Global review and estimates publication-title: Ophthalmic Epidemiol doi: 10.1080/09286586.2021.1962919 – volume: 191 start-page: S97 issue: Suppl 1 year: 2005 ident: 10.1016/j.vaccine.2024.01.044_b0180 article-title: Role of herd immunity in determining the effect of vaccines against sexually transmitted disease publication-title: J Infect Dis doi: 10.1086/425271 – volume: 44 start-page: 763 issue: 12 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0225 article-title: Performance of commercial enzyme-linked immunoassays for diagnosis of herpes simplex virus-1 and herpes simplex virus-2 infection in a clinical setting publication-title: Sex Transm Dis doi: 10.1097/OLQ.0000000000000689 – volume: 218 start-page: 1890 issue: 12 year: 2018 ident: 10.1016/j.vaccine.2024.01.044_b0430 article-title: Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex Virus-2, on Viral shedding and lesions: results of a randomized placebo-controlled trial publication-title: J Infect Dis doi: 10.1093/infdis/jiy415 – volume: 89 start-page: 8206 issue: 16 year: 2015 ident: 10.1016/j.vaccine.2024.01.044_b0160 article-title: Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins publication-title: J Virol doi: 10.1128/JVI.01302-15 – volume: 5 start-page: 104 issue: 1 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0465 article-title: The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model publication-title: npj Vaccines doi: 10.1038/s41541-020-00254-8 – volume: 5 start-page: e001875 issue: 3 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0080 article-title: The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study publication-title: BMJ Glob Health doi: 10.1136/bmjgh-2019-001875 – volume: 11 start-page: 94 issue: 3 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0065 article-title: Neonatal herpes simplex virus infection: Epidemiology and outcomes in the modern era publication-title: J Pediatric Infect Dis Soc doi: 10.1093/jpids/piab105 – volume: 12 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0045 article-title: Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression publication-title: Lancet Reg Health West Pac – volume: 8 start-page: 199 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0110 article-title: Herpes simplex virus type 2 Myelitis: Case report and review of the literature publication-title: Front Neurol doi: 10.3389/fneur.2017.00199 – volume: 169 start-page: 1233 issue: 13 year: 2009 ident: 10.1016/j.vaccine.2024.01.044_b0265 article-title: A pooled analysis of the effect of condoms in preventing HSV-2 acquisition publication-title: Arch Intern Med doi: 10.1001/archinternmed.2009.177 – volume: 30 start-page: 226 issue: 3 year: 2003 ident: 10.1016/j.vaccine.2024.01.044_b0245 article-title: Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes: a randomized study publication-title: Sex Transm Dis doi: 10.1097/00007435-200303000-00010 – volume: 131 issue: 9 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0360 article-title: B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin publication-title: J Clin Invest doi: 10.1172/JCI142088 – volume: 39 start-page: 388 issue: 5 year: 2012 ident: 10.1016/j.vaccine.2024.01.044_b0270 article-title: Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition publication-title: Sex Transm Dis doi: 10.1097/OLQ.0b013e318248aa8a – volume: 98 start-page: 315 issue: 5 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0010 article-title: Herpes simplex virus: global infection prevalence and incidence estimates, 2016 publication-title: Bull World Health Organ doi: 10.2471/BLT.19.237149 – volume: 7 start-page: 44084 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0165 article-title: Worldwide circulation of HSV-2 × HSV-1 recombinant strains publication-title: Sci Rep doi: 10.1038/srep44084 – volume: 9 start-page: p. ofac494 issue: 10 year: 2022 ident: 10.1016/j.vaccine.2024.01.044_b0260 article-title: Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofac494 – volume: 14 start-page: e1002475 issue: 12 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0155 article-title: Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study publication-title: PLoS Med doi: 10.1371/journal.pmed.1002475 – ident: 10.1016/j.vaccine.2024.01.044_b0330 – volume: 4 start-page: 33 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0375 article-title: Successful application of prime and pull strategy for a therapeutic HSV vaccine publication-title: NPJ Vaccines doi: 10.1038/s41541-019-0129-1 – volume: 14 start-page: e0226320 issue: 12 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0440 article-title: Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial publication-title: PLoS One doi: 10.1371/journal.pone.0226320 – volume: 178 start-page: 603 issue: 3 year: 1998 ident: 10.1016/j.vaccine.2024.01.044_b0240 article-title: Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group publication-title: J Infect Dis doi: 10.1086/515385 – volume: 371 start-page: 2109 issue: 9630 year: 2008 ident: 10.1016/j.vaccine.2024.01.044_b0285 article-title: Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(08)60920-4 – volume: 90 year: 2023 ident: 10.1016/j.vaccine.2024.01.044_b0490 article-title: The population impact of herpes simplex virus type 2 (HSV-2) vaccination on the incidence of HSV-2, HIV and genital ulcer disease in South Africa: a mathematical modelling study publication-title: EBioMedicine doi: 10.1016/j.ebiom.2023.104530 – volume: 289 start-page: 203 issue: 2 year: 2003 ident: 10.1016/j.vaccine.2024.01.044_b0135 article-title: Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant publication-title: JAMA doi: 10.1001/jama.289.2.203 – ident: 10.1016/j.vaccine.2024.01.044_b0035 – ident: 10.1016/j.vaccine.2024.01.044_b0310 – volume: 5 start-page: e300 issue: 3 year: 2017 ident: 10.1016/j.vaccine.2024.01.044_b0060 article-title: First estimates of the global and regional incidence of neonatal herpes infection publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(16)30362-X – volume: 341 start-page: 1432 issue: 19 year: 1999 ident: 10.1016/j.vaccine.2024.01.044_b0150 article-title: A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group publication-title: N Engl J Med doi: 10.1056/NEJM199911043411904 – volume: 123 start-page: 845 issue: 11 year: 1995 ident: 10.1016/j.vaccine.2024.01.044_b0205 article-title: Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women publication-title: Ann Intern Med doi: 10.7326/0003-4819-123-11-199512010-00006 – volume: 122 start-page: 2057 issue: 13 year: 2016 ident: 10.1016/j.vaccine.2024.01.044_b0530 article-title: Racial and ethnic disparities in human papillomavirus-associated cancer burden with first-generation and second-generation human papillomavirus vaccines publication-title: Cancer doi: 10.1002/cncr.30007 – volume: 280 start-page: 61 issue: 1 year: 1998 ident: 10.1016/j.vaccine.2024.01.044_b0210 article-title: Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men publication-title: JAMA doi: 10.1001/jama.280.1.61 – volume: 203 start-page: 1434 issue: 10 year: 2011 ident: 10.1016/j.vaccine.2024.01.044_b0170 article-title: Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa publication-title: J Infect Dis doi: 10.1093/infdis/jir047 – volume: 6 start-page: e04368 issue: 7 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0480 article-title: Dynamics of HSV-2 infection with a therapeutic vaccine publication-title: Heliyon doi: 10.1016/j.heliyon.2020.e04368 – volume: 35 year: 2021 ident: 10.1016/j.vaccine.2024.01.044_b0050 article-title: Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2021.100876 – volume: 37 start-page: 7408 issue: 50 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0515 article-title: Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017 publication-title: Vaccine doi: 10.1016/j.vaccine.2017.10.084 – volume: 10 start-page: 373 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0355 article-title: Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design publication-title: Front Immunol doi: 10.3389/fimmu.2019.00373 – volume: 32 start-page: 1630 issue: 14 year: 2014 ident: 10.1016/j.vaccine.2024.01.044_b0315 article-title: Vaccines against sexually transmitted infections: the way forward publication-title: Vaccine doi: 10.1016/j.vaccine.2014.01.053 – volume: 11 start-page: e0160707 issue: 8 year: 2016 ident: 10.1016/j.vaccine.2024.01.044_b0520 article-title: Assessment of the broader economic consequences of HPV prevention from a government-perspective: A fiscal analytic approach publication-title: PLoS One doi: 10.1371/journal.pone.0160707 – volume: 68 start-page: 1783 issue: 10 year: 2019 ident: 10.1016/j.vaccine.2024.01.044_b0130 article-title: Herpes simplex virus type 1 genital ulcer disease at a tertiary care hospital in north india publication-title: Clin Infect Dis doi: 10.1093/cid/ciy943 – volume: 34 start-page: 2939 issue: 26 year: 2016 ident: 10.1016/j.vaccine.2024.01.044_b0025 article-title: The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps publication-title: Vaccine doi: 10.1016/j.vaccine.2016.03.111 – volume: 14 start-page: 398 issue: 4 year: 2020 ident: 10.1016/j.vaccine.2024.01.044_b0405 article-title: Herpes Simplex virus type 2 seroprevalence and risk factors among adolescents and youth with HIV-1 in Northern publication-title: Tanzania J Infect Dev Ctries doi: 10.3855/jidc.11599 – volume: 375 start-page: 666 issue: 7 year: 2016 ident: 10.1016/j.vaccine.2024.01.044_b0005 article-title: Genital herpes publication-title: N Engl J Med doi: 10.1056/NEJMcp1603178 |
| SSID | ssj0005319 |
| Score | 2.4897556 |
| SecondaryResourceType | review_article |
| Snippet | Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the world. HSV-2... AbstractHerpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are chronic, highly prevalent viral infections that cause significant morbidity around the... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S82 |
| SubjectTerms | Allergy and Immunology childhood Children Disease control Disease prevention Epidemiology Eye diseases Government agencies Herpes Genitalis - immunology Herpes Genitalis - prevention & control Herpes simplex Herpes Simplex - immunology Herpes Simplex - prevention & control Herpes simplex virus Herpes Simplex Virus Vaccines - administration & dosage Herpes Simplex Virus Vaccines - immunology Herpes viruses Herpesvirus 1, Human - immunology Herpesvirus 2, Human - immunology HIV Human alphaherpesvirus 1 Human immunodeficiency virus Humans Immunization Morbidity Neonates Neurological diseases Nonprofit organizations Organizations people Public health risk Sexually transmitted diseases social benefit STD Vaccination Vaccine Vaccines viruses |
| SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3ZatwwcAiBlr6UZnttLlQoeYp3ZUm25ccSEkIhJdAk7JvQFdhQNku8G5qXfntHsuxtyVX6YrA9YwnNaA5rDoDPLr9kBk35zLnCZ6I2PtNUu8yV9JKG5BIdD9pPvpXH5-LrpJiswUGXCxPCKpPsb2V6lNbpyTit5ng-nY6_06jL6SREQdIi-u2h-hfy9OjXH2EePDb3CMBZgF5l8YyvRrfahuNrdBOZiNU7hXhMPz1mf0Y9dPQGXicDknxp57gBa342gBdtS8m7Abw8SYflA9g7bctS3-2Ts1WWVbNP9sjpqmA14gwuQkxMTMwlHfpbGF200yahHrgnqbk3QSOX4NfmviHNNJQW_klupzfL5h2cHx2eHRxnqbtCZgvJFug4CuasKYURwhkutKtzzZFiprKV9FzKoqwtGmAozbVktgjOmbS-NhVDWMrfw_rseuY_AuEG9T7qOU0dmjMSBRfqQ7xYnuN3ajsE0a2psqn0eOiA8UN1MWZXKpFCBVIomiskxRBGPdq8rb3xHELZEUx1iaUoChVqh-cQq4cQfZM2dKNy1TBF1T2mG4LsMf_i238ZdLvjKdWPgyIX_XpWVXIIn_rXuOXDOY6e-etlC4NuLRdPwaAmQ9MrL3GGH1p-7deQ19ERlpv_P_cteBXuwk9uVmzD-uJm6XfQOluY3bj9fgNsszWG priority: 102 providerName: Elsevier |
| Title | Vaccine value profile for herpes simplex virus |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X24000550 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X24000550 https://dx.doi.org/10.1016/j.vaccine.2024.01.044 https://www.ncbi.nlm.nih.gov/pubmed/39003018 https://www.proquest.com/docview/3079782778 https://www.proquest.com/docview/3079956348 https://www.proquest.com/docview/3153661160 |
| Volume | 42 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: ACRLP dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AIKHN dateStart: 20091030 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1873-2518 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: AKRWK dateStart: 19831201 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 7X7 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: BENPR dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1873-2518 dateEnd: 20250801 omitProxy: true ssIdentifier: ssj0005319 issn: 0264-410X databaseCode: 8C1 dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1RT9swED4N0CakadqyDbox5EkTT6Q4jpM4T4ghULeJqtoA5c1KbCOBpraQFo2X_XbOsZO8DNhLEqk-x83Zd9_5fHcAX3R0wSqE8qHWiQl5XpmwpKUOdUovqA0uKRtH-8k4HZ3x70VS-A232h-rbGViI6j1TNk98j2ci2jwsCwT-_Pr0FaNst5VX0JjBdYihCp2VmdF1h_xiJvCHmhm8JBHtOgjePauhrelsq5rNBEZbzJ3cv6QbnoIezY66Pg1vPLgkRw4br-BZ2YawHNXTvIugBcn3lEewM7EpaS-2yWnfYRVvUt2yKRPVo00L92-HXHhSAEE5_Z8TBOkS9ru3sLw3P0NYnODG-ILfRMEvAR7n5ua1Jc2zfAfcnt5s6zfwdnx0enhKPSVFkKVCLZAI5IzraqUV5zrKualzqMyRu5VmcqEiYVI0lwhGEPJXgqmEmuoCWXyKmPYlsbvYXU6m5pNIHGFGAB1Xkk1QhuBQgx1I15UHGE_uRoAb7-xVD4Nua2G8Vu2582upGeNtKyRNJLImgEMO7K5y8PxFEHaMlC2QaYoFiVqiqcIs38Rmtov7lpGsmaSyl-0AZO0sMdwKVp6AxAdpccvDpf8z0u32jkmu_f0U34An7ufcflbn045NbOla4Mmbswfa4NaDWFYlOIIN9z87b5hnDdGsfjw-AA-wrodrd3UZskWrC5uluYTorFFtQ0rw7_RdrPw8CoO8Xnt4NuP0RjvX4_Gk5_3yWw1dg |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIT4khCDAKAwwEuxp6RzbSZwHhBAwdWydJtFNeTOJ7UmbprYs7aD_FH8j5zhJX9jGy176Up_j5Oy73_m-AN6Z6JiVCOVDY2Ibiqy0YUELE5qEHlOXXFLUjvbhfjI4FN_yOF-BP20ujAurbGViLajNRLs78i3ci2jwsDSVH6c_Q9c1ynlX2xYaflvs2sUvNNmqDztfkL_vGdv-Ovo8CJuuAqGOJZuhwSSY0WUiSiFMyUVhsqjguNIy1am0XMo4yTQCD5RihWQ6dkaJ1DYrU4ZjKcd5b8FtwalwtfrTPF2GlPC6kQiaNSIUEc2XGUNbp_2LQjtXOZqkTNSVQoW4TBdehnVrnbf9CB42YJV88rvrMazYcQB3fPvKRQB3h41jPoCNA18Ce7FJRsuMrmqTbJCDZXFspHng7wmJT38KIDhy8Th1UjBpp3sC_SP_GsTVIrekaSxOEGATnH1qK1KduLLGv8nFyfm8egqHN8KDZ7A6noztcyC8RMyBOragBqGURKGJuhh_NI9wnkz3QLTfWOmm7LnrvnGm2vi2U9WwRjnWKBopZE0P-h3Z1Nf9uI4gaRmo2qRWFMMKNdN1hOm_CG3VCJNKRapiiqrvtAavNHdhvxQtyx7IjrLBSx4H_c9D19s9prrnLI9YD952f6O4cT6kYmwncz8GTWourhqDWhRhX5TgCtf8_u2-Ic9qI1y-uHoBb-DeYDTcU3s7-7sv4b5bubtQZ_E6rM7O5_YVIsFZ-bo-fgR-3PR5_wuyEm0_ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NISYkhCB8FQYYCfa0tI7tJM4DQohRbYxNldimvJnEdqVNqC1LO-i_xl_HOU6aF7bxspe-1Oc4Ofvud74vgLcmGrMSoXxoTGxDkZU2LGhhQpPQMXXJJUXtaD84THaPxZc8ztfgT5sL48IqW5lYC2oz1e6OfIB7EQ0elqZyMG7CIkY7ww-zn6HrIOU8rW07Db9F9u3yF5pv1fu9HeT1O8aGn48-7YZNh4FQx5LN0XgSzOgyEaUQpuSiMFlUcFx1mepUWi5lnGQaQQhKtEIyHTsDRWqblSnDsZTjvLfgdsoFd-FkaZ524SW8biqCJo4IRUTzLntocNa_KLRzm6N5ykRdNVSIy_TiZbi31n_DB3C_Aa7ko99pD2HNTgK441tZLgPYOGic9AFsjXw57OU2Oeqyu6ptskVGXaFspLnn7wyJT4UKIDhxsTl1gjBpp3sE_RP_GsTVJbekaTJOEGwTnH1mK1KduhLHv8nF6fmiegzHN8KDJ7A-mU7sMyC8RPyB-ragBmGVRAGKehl_NI9wnkz3QLTfWOmmBLrrxPFDtbFuZ6phjXKsUTRSyJoe9FdkM18D5DqCpGWgahNcUSQr1FLXEab_IrRVI1gqFamKKaq-0RrI0tyFAFO0MnsgV5QNdvKY6H8eutnuMbV6TnfcevBm9TeKHudPKiZ2uvBj0Lzm4qoxqFERAkYJrvCp37-rb8iz2iCXz69ewGvYwJOuvu4d7r-Au27h7m6dxZuwPj9f2JcICuflq_r0Efh-08f9LxJDcXo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccine+value+profile+for+herpes+simplex+virus&rft.jtitle=Vaccine&rft.au=Johnston%2C+Christine&rft.au=Scheele%2C+Suzanne&rft.au=Bachmann%2C+Laura&rft.au=Boily%2C+Marie-Claude&rft.date=2024-07-25&rft.issn=0264-410X&rft.volume=42&rft.issue=19+p.S82-S100&rft_id=info:doi/10.1016%2Fj.vaccine.2024.01.044&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X24X00213%2Fcov150h.gif |